| Identification | Back Directory | [Name]
2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine | [CAS]
927871-76-9 | [Synonyms]
S107
CS-2452
S-107; S 10
S 107 hydrochloride
2,3,4,5-Tetrahydro-7-methoxy-4-methyl-
2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine
1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-methyl-
7-methoxy-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine | [Molecular Formula]
C11H15NOS | [MDL Number]
MFCD12546447 | [MOL File]
927871-76-9.mol | [Molecular Weight]
209.31 |
| Chemical Properties | Back Directory | [Boiling point ]
318.8±42.0 °C(Predicted) | [density ]
1?+-.0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: 100mg/mL | [form ]
neat | [pka]
7.74±0.20(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water : ≥ 132 mg/mL (537.09 mM) | [BRN ]
18342799 | [InChIKey]
BGVCEGVSQDOGSB-UHFFFAOYSA-N | [SMILES]
S1CCN(Cc2c1ccc(c2)OC)C |
| Hazard Information | Back Directory | [Uses]
It is a benzothiazepine derivative that binds the RyR1 channel and enhances the binding affinity of Calstabin-1. By preventing the depletion of Calstabin-1 from the RyR1 complex, S 107 slows muscle fatique and reduces muscle damage in exercised mice. In a murine model of Duchenne muscular dystrophy, S 107 reduces biochemical and histological evidence of the muscle damage associated with muscular dystrophy, improves muscle function, and increases exercise performance. | [Biological Activity]
Primary Target
RyR2 | [in vivo]
S107, which prevents a leak in the channel but does not block the channel or alter normal Ca2+ signaling, is able to inhibit both seizures and arrhythymias in the mutant mice[1].
|
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|